Diffusion of certain guidelines, addressing all of the aspects in the use of LAI antipsychotics, will boost clinicians’ perceived competence. It will also help to increase the percentage of sufferers to whom LAI antipsychotics will be presented by psychiatrists as a therapeutic choice. The objective of these recommendations would be to propose a prescription framework to clinicians for the usage of a specific formulation of antipsychotics (LAI) in diverse therapeutic indications and precise clinical scenarios. The aim would be to permit clinicians to present probably the most suitable pharmaceutical techniques for the patients and to facilitate the use of LAI antipsychotics in clinical practice. The recommendations presented right here from a consensus-based recommendations methodology (Formal Consensus Suggestions) arebased on scientific information as well as the consensus of a panel of experts.MethodsQuestionnaire developmentInitially, we performed an analysis and a literature review regarding the indications and the use of LAI antipsychotics. A literature search making use of the key phrases “antipsychotic”, “neuroleptic”, “first-generation antipsychotic”, “atypical antipsychotic”, “second-generation antipsychotic”, “long-acting injectable”, “depot”, “depot neuroleptic” was performed in PubMed and EMBASE to discover all of the relevant studies published. Further references have been identified from http:www.fda.gov and http: www.ema.europa.eu. Information from all of those sources was discussed and an overview of your current proof has been graded and summarized applying the French National Authority for Wellness (HAS) “levels of evidence” criteria [16]. Following this initially step, the scientific committee (PML, LS, MA, Pc, SG, SL) produced a questionnaire consisting of 32 inquiries that covered 539 therapeutic solutions. The 32 concerns have been regrouped into three areas PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21310042 that have been judged as vital: Target-population: Description with the unique indications with the LAI antipsychotics and with the most appropriate period in the illness to introduce the therapy. Prescription and use: Choice from the molecule, techniques of introduction, distinct approaches according to the psychiatric disorder or comorbidities, and therapy monitoring. Specific population: Use of LAI antipsychotics in pregnant ladies, elderly patients, subjects within a precarious circumstance, and subjects possessing to become treated inside a prison establishment. This questionnaire was created to become completed by an experts’ panel. The time expected for its administration was estimated at around three hours. At the time of development, each of the LAI antipsychotics out there in France were proposed as therapeutic selections (Table 1). They were regrouped into two categories: Long-acting injectable first-generation antipsychotics (LAI FGA). Long-acting injectable second-generation antipsychotics (LAI SGA). This artificial separation FGASGA is not consensual on account of their heterogeneous profiles of efficacyLlorca et al. BMC Psychiatry 2013, 13:340 http:www.biomedcentral.com1471-244X13Page 3 ofTable 1 LAI antipsychotics offered in France (when the survey was completed)LAI second-generation antipsychotics LAI first-generation antipsychotics Risperidone microsphere FIIN-2 supplier Olanzapine pamoate Haloperidol decanoate Zuclopenthixol decanoate Flupentixol decanoate Fluphenazine decanoate Pipotiazine palmitateNote: as paliperidone palmitate had a advertising and marketing authorization date soon after the improvement of those guidelines, it couldn’t be taken into account.Specialist selectionThe Scientific Committee (Appendix 1) sel.
